ABL1 and breast cancer: We first wished to demonstrate clinically relevant activity of IB in CML cells, so primary CD34+ CML-CP cells and BCR-ABL1+ human CML-BC cell lines were incubated with the drug in vitro and total viable cell counts performed by Trypan Blue dye exclusion after 72 h.